Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer
ITB discussions improve survival in mCRPC patients, mainly due to personalized approaches and better access to clinical trials. Visceral and symptomatic metastases as well as renal impairment are risk factors for reduced OS, emphasizing the need for careful management of these high-risk patients. The results support the expanded use of ITB to improve mCRPC treatment outcomes.
Authors
- Igor Tsaur (ORCID: https://orcid.org/0000-0001-5107-3523)
- Alain Rudiger (ORCID: https://orcid.org/0000-0001-7943-7624)
- Eva Erne (ORCID: https://orcid.org/0000-0003-3478-7625)
- Laura Lawaczeck
- Jörg Hennenlotter (ORCID: https://orcid.org/0000-0003-3827-6996)
- Steffen Rausch (ORCID: https://orcid.org/0000-0002-6398-8701)
- Simon Walz (ORCID: https://orcid.org/0000-0003-3757-158X)
- Joël Hammes
- Valentina Spingler
Institutions
- Klinik und Poliklinik für Urologie (DE)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1007/s00432-025-06135-8
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Universitätsklinikum Tübingen